Independent Factors Associated with Opioid Refills at 31-60 and 61-90 Days After Spine Surgery

Fang Ye, MD, PhD[1,2]*, Lingyi Zhang, MD[1]*, Praveen V. Mummaneni, MD, MBA[3], Akash Shanmugam[4], Andrew Bishara, MD[1], Sigurd H. Berven, MD[5], Christopher R. Abrecht, MD[1], and Zhonghui Guan, MD[1]

[1]Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America

[2]Anesthesiology Department, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China

[3]Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, United States of America

[4]University of California San Francisco School of Medicine, San Francisco, CA, United States of America

[5]Department of Orthopaedic Surgery, University of California, San Francisco, San Francisco, CA, United States of America

*These authors contributed equally.

Corresponding Author

Zhonghui Guan, MD

Department of Anesthesia and Perioperative Care

University of California San Francisco

520 Illinois St

San Francisco, CA 94158

Tel: 415-885-7246

Fax: 415-885-7575

zhonghui.guan@ucsf.edu

Acknowledgement: The authors thank Athalia Grazette for the data collection.

Word and Element Counts:

Abstract: 300

Introduction: 390

Discussion: 1207

Number of figures: 3

Number of tables: 2

Number of supplementary figures: 2

Running head: Risk Factors for Opioid Refill after Spine Surgery

Funding Statement: The research is not funded.

Conflicts of Interest: P.V.M. has served as a consultant for DePuy Spine, Globus, and Stryker; has direct stock ownership in Spinicity/ISD; has received royalties from DePuy Spine, Thieme

Publishers, and Springer Publishing; and has received support from ISSG, NREF, NIH, and AOSpine for non-study-related clinical or research efforts. The other authors declare that they have no conflicts of interest.

Abbreviations and acronyms:

aOR: adjusted odds ratio

BMI: body mass index

CDC: Centers for Disease Control and Prevention

CI: confidence interval

IQR: interquartile range

LOS: length of stay

NPV: negative predictive value

OME: oral morphine equivalent

PPV: positive predictive value

TPS: transitional pain service

UCSF: University of California San Francisco

ABSTRACT

Background: Although transitional pain service (TPS) has been proposed to manage patients at risk for persistent postsurgical opioid use, no standard criteria exist to identify high-risk patients for TPS management. Specifically, the 2-3 months following surgery are critical for the transition from short-term to persistent opioid use, yet little is known about opioid refills during this period.

Methods: This retrospective cohort study included 11,087 adult patients, regardless of opioid-naïve status, who underwent spine surgery at an academic medical center and were discharged between January 2017 and December 2023. Data were analyzed using multiple logistic and linear regressions and Fisher's exact test.

Results: Of the patients, 25.4% and 14.8% received opioid refills at 31-60 and 61-90 days post-discharge, respectively. Among the independent risk factors, a refill at 31-60 days was the strongest predictor of a refill at 61-90 days (aOR 6.71, 95% CI 5.90-7.65), regardless of preoperative opioid use, cervical or lumbar procedures, or surgical service. Refill rates at 31-60 and 61-90 days were linearly correlated ($p<0.0001$, slope=0.73). A refill at 31-60 days predicted a refill at 61-90 days with a negative predictive value (NPV) of 94.3% and a positive predictive value of 41.5%, with consistently high NPVs across subgroups defined by preoperative opioid use, surgical procedure, or surgeon. A refill at 1-30 days; preoperative use of opioids, marijuana, and benzodiazepine; the first postoperative pain score recorded on hospital floor; and depression were all associated with increased odds of refills at both 31-60 and 61-90 days. In contrast, the total dose of discharge opioid prescriptions had minimal impact on refills.

Conclusion: A refill at 31-60 days after discharge may serve as a screening marker for identifying high-risk patients who could benefit from TPS management to mitigate further opioid use. Moreover, each refill prescription should be carefully managed to prevent subsequent refills.

INTRODUCTION

Persistent opioid use after surgery is a major medical concern among postsurgical patients[1-4]. Some patients continue using opioids 12 months after their surgical procedures[5-11], requiring considerably more healthcare services[12]. Additionally, patients prescribed opioids after surgery may misuse them or divert them to others[13], with the risk of such behaviors increasing with each opioid refill and every additional week of opioid use[14,15].

To help prevent prolonged postsurgical opioid use, transitional pain service (TPS) programs have been proposed to manage high-risk patients[1,16]. However, there is currently no standardized method to identify high-risk patients for TPS management, as each TPS program employs its own patient-selection criteria, making comparisons between different TPS programs and multi-center clinical trials difficult. Importantly, current patient-section criteria often fail to identify many patients who may benefit from TPS, as many so-called low-risk patients, such as opioid-naïve individuals who do not use opioids before surgery[17-19] or those undergoing low-risk surgical procedures[2,20,21], also develop persistent postsurgical opioid use.

Approximately 900,000 American adults undergo spine surgery annually[22]. Following cervical spine surgery, 6.3% of opioid-naive patients and 45.3% of non-opioid-naïve patients continued using opioids 12 months post-surgery[5]. After lumbar spine surgery, 8.6% of opioid-naive patients and 42.4% of non-opioid-naïve patients continued using opioids at 12 months[6]. By the third month after spine surgery, opioid use rates decreased substantially compared to the first and second months but were similar to those observed at 12 months post-surgery[5,6].

While opioid use within the first month after surgery is considered immediate short-term use[23], use beyond three months after surgery is classified as persistent opioid use[24,25]. Thus, the two- to three-month period after surgery represents a critical transitional phase from short-term to persistent opioid use. Although previous studies have examined risk factors associated with acute opioid use within the first postsurgical month[23] and persistent opioid use beyond three months[20,21,26-30], little is known about opioid use during the transitional two to three months postsurgical period for any type of surgical procedure, including spine surgery.

This study included 11,087 adult patients, regardless of opioid-naïve status, who underwent spine surgery, a procedure associated with high rates of persistent post-surgical opioid use[5,6]. The study aimed to identify independent risk factors associated with opioid refills at 31-60 days and 61-90 days after discharge and to develop a simple screening marker to detect high-risk patients likely to require further opioid refills following spine surgery.

METHODS

Study Design and Data Source

This retrospective observational cohort study was approved by the University of California San Francisco (UCSF) Institutional Review Board, which waived the requirement for patient consent to access electronic health record data.

Study Cohort

The cohort included 11,087 adult patients, regardless of opioid-naïve status, who underwent spine surgery performed by orthopedic spine and neuro-spine services at the UCSF Medical Center. Patients had postsurgical hospital stays of at least 1 day and were discharged between January 2017 and December 2023, a period following the release of the 2016 Centers for Disease Control and Prevention (CDC) guidelines for opioid prescriptions[31].

Outcome and Variables

The primary outcome was opioid refills prescribed at 31-60 and 61-90 days after hospital discharge. The study did not extend beyond 90 days, as many patients obtained opioid refills from their primary care physicians outside of the UCSF system after three months post-surgery, resulting in incomplete refill records beyond this period. Variables include preoperative opioid (within 6 months before surgery), marijuana, and benzodiazepine usage, first postsurgical pain level on hospital floor, last pain level before discharge, intra-operative oral morphine equivalents (OME), inpatient first daily OME after surgery, inpatient last daily OME before discharge, total OME of prescribed opioids at discharge, postsurgical usage of non-opioid analgesics

(acetaminophen, non-steroidal anti-inflammatory drugs [NSAIDs], and gabapentinoids), opioid refill prescriptions at 1-30 days after discharge, type of the procedures (elective procedure, laminectomy, tumor resection, spine fusion, cervical procedures, lumbar procedures), surgical procedures (anterior cervical discectomy and fusion, anterior lumbar spine fusion 2-4 segments, cervical laminoplasty, endoscopic posterior spine fusion 1-2 segments, lateral lumbar interbody fusion, laminectomy for spinal cord tumor resection, lumbar decompression, posterior cervical spine fusion 4-7 segments, posterior lumbar spine fusion 1-3 segments, posterior lumbar spine fusion 4-6 segments, posterior lumbar fusion 7-12 segments, posterior spine fusion ≥13 segments, and posterior spine fusion with resection of spine tumor), neuro-spine vs ortho-spine service, procedure time in the operating room, return to operating room before discharge, postsurgical hospital length of stay (LOS), discharge disposition, psychiatric comorbidities (depression and anxiety), body mass index (BMI), age, sex, race, and ethnicity.

All opioid doses were converted to OME[32]. Similar to previous studies[33-36], opioid daily dose over-prescription was defined as a maximum prescribed daily dose exceeding the patient's last inpatient daily opioid consumption before discharge by at least 7.5 OME, while under-prescription was defined as a maximum prescribed daily dose of at least 7.5 OME below the patient's last inpatient daily opioid consumption before discharge. 7.5 MME was set as the threshold because it corresponds to the dose of a 5 mg Oxycodone pill, the opioid medication most commonly prescribed opioid after surgery[37], making it a clinically practical range for aligning daily doses.

Statistical Analyses

Continuous variables, determined to be abnormally distributed by the D'Agostino and Pearson tests, were presented as medians with interquartile ranges (IQR). Binary variables were presented as percentages and analyzed using simple linear regression. Negative and positive predictive values were assessed using two-sided Fisher's exact test. Multiple logistic regression was performed using the area under the ROC curve, a classification table, and predicted probability for each subject as classification and prediction methods, and the results were presented as adjusted odds ratios (aOR) and 95% confidence intervals (CI). All analyses were conducted using GraphPad Prism 10.3.1, with the statistical significance set at an α value of 0.05.

RESULTS

Demographic Data

As shown in Table 1, among the cohort of 11,087 patients with a median age of 64 years (IQR 54-72), 5,744 (51.8%) self-identified as female, 8,075 (72.8%) as white, 883 (8.0%) as Asian, 632 (5.7%) as black, 163 (1.5%) as Native American or Alaska Natives, 59 (0.5%) as Native Hawaiian or other Pacific Islanders, and 1,151 (10.4%) as Hispanic or Latino. Additionally, 6,243 (56.3%), 2,115 (19.1%), and 2,071 (18.7%) patients had preoperative use of opioids (within six months before surgery), marijuana, and benzodiazepines, respectively. During postoperative hospitalization, 10,386 (93.7%) patients received acetaminophen, 399 (3.6%) received NSAIDs, and 9974 (90.0%) received gabapentinoids (gabapentin or pregabalin).

A total of 4,151 (37.4%), 2,819 (25.4%), and 1,640 (14.8%) patients received opioid refills at 1-30, 31-60, and 61-90 days after discharge, respectively. The median first pain level recorded on the hospital floor and last pain level recorded before discharge were 6 (IQR 3-8) and 5 (IQR 3-6) on a 0-10 scale, respectively. The median OMEs for intra-operative use, the first inpatient postsurgical daily consumption on the hospital floor, the last inpatient daily consumption before discharge, and the total dose of discharge opioid prescriptions were 106.6 (IQR 67.2-204.0), 110.0 (IQR 55.8-199.8), 75.0 (IQR 30.0-132.5) and 450 (IQR 0.0-900.0), respectively. A total of 5,149 (46.6%) patients were overprescribed opioid daily doses at discharge, while 4,438 (40.0) were under-prescribed.

Previous Opioids Refills are Strongly Associated with Subsequent Opioid Refills

Our multiple logistic regression analyses (Table 2) revealed that, when controlling for other factors, an opioid refill at 31-60 days after discharge was the strongest risk factor associated with an increased odds of opioid refill at 61-90 days (aOR 6.71, 95% CI 5.90-7.65). Additionally, an opioid refill at 1-30 days was strongly associated with increased odds of refills at both 61-90 days (aOR 3.16, 95% CI 2.76-3.62) and 31-60 days (aOR 4.04, 95% CI 3.66-4.46) after discharge.

Other Postoperative Factors Associated with Opioid Refills at 31-60 and 61-90 Days After Discharge

Multiple logistic regression analyses also revealed that when other factors were controlled, postsurgical acetaminophen (aOR 0.55, 95% CI 0.43-0.72) was associated with reduced odds of opioid refill at 61-90 days after discharge. Discharge to home or self-care was associated with reduced odds of refills at 61-90 days (aOR 0.82, 95% CI 0.70-0.96) and 31-61 days (aOR 0.84, 95% CI 0.75-0.95) after discharge, respectively.

Additionally, higher first postsurgical pain levels recorded on the ward floor were associated with increased odds of opioid refill at 61-90 (aOR 1.05, 95% CI 1.02-1.07) and 31-60 days (aOR 1.03, 95% CI 1.02-1.05), whereas higher last pain levels recorded before discharge were associated with an increased odds of refill at 31-60 days (aOR 1.07, 95% CI 1.05-1.09). The intraoperative OME, the first postoperative inpatient daily OME on hospital floor, and the last inpatient daily OME before discharge were not associated with increased or decreased odds of opioid refills. However, a higher total dose of discharge opioid prescription was associated with an increased odd of opioid refill at 31-60 days (aOR 1.00008, 95% CI 1.00004-1.00012), but not

at 61-90 days after discharge. Opioid daily dose under-prescription at discharge was associated with an increased odds of refill at 61-90 days (aOR 1.33, 95% CI 1.08-1.64), while opioid daily dose over-prescription was not associated with opioid refills.

Preoperative Factors Associated with Opioid Refills at 31-60 and 61-90 Days After Discharge

Preoperative opioid use within 6 months before surgery was associated with increased odds of opioid refills at 61-90 days (aOR 1.68, 95% CI 1.45-1.95) and 31-60 days (aOR 1.86, 95% CI 1.67-2.08) after discharge. Preoperative use of marijuana (aOR 1.25, 95% CI 1.08-1.45) and benzodiazepine (aOR 1.17, 95% CI 1.01-1.35), as well as depression (aOR 2.03, 95% CI 1.38-2.99), were also associated with an increased odds of refills at 61-90 days after discharge. Similarly, preoperative use of marijuana (aOR 1.26, 95% CI 1.12-1.42) and benzodiazepine (aOR 1.16, 95% CI 1.03-1.30), and depression (aOR 1.404, 95% CI 1.002-1.962), were also associated with increased odds of refills at 31-60 days after discharge as well. Age, sex, race, ethnicity, anxiety, and BMI were not associated with opioid refills, except that being black was associated with an increased odds of refill at 61-90 days (aOR 1.47, 95% CI 1.05-2.04).

Association between Surgical Procedures and Opioid Refills at 31-60 and 61-90 Days After Discharge

Compared to orthopedic spine surgery, neuro-spine surgery was associated with decreased odds of opioid refills at 61-90 (aOR 0.64, 95% CI 0.55-0.73) and 31-60 days (aOR 0.67, 95% CI 0.60-0.74) when other factors were controlled. Overall, specific spine surgical procedures were generally not associated with increased or decreased odds of opioid refills. However, endoscopic posterior spine fusion of 1-2 segments was associated with a decreased odds of opioid refill at

61-90 days (aOR 0.58, 95% CI 0.36-0.91), while anterior spine fusion of 2-4 segments (aOR 1.30, 95% CI 1.07-1.57) and posterior spine fusion of 7-12 segments (aOR 1.37, 95% CI 1.08-1.74) were associated with an increased odds of opioid refill at 31-60 days.

Trends in the Rates of Opioid Refill at 31-60 and 61-90 Days After Discharge

We analyzed the opioid refill rates at 31-60 and 61-90 days from 2017 to 2023 at six-month intervals. The refill rate at 31-60 days decreased significantly during this period ($p = 0.003$, slope = -0.39) (Figure 1a). When the refill rate at 31-60 days was plotted against that at 61-90 days, a linear correlation was observed ($p < 0.0001$, slope = 0.73) (Figure 1b).

Strong Association Between Opioid Refills at 31-60 and 61-90 Days in Patients With and Without Pre-operative Opioids, Following Cervical and Lumbar Spine Surgeries, and by Neurosurgery and Orthopedic Services

Our multiple logistic regression analyses showed that, with other factors controlled, a refill at 31-60 was strongly associated with increased odds of refill at 61-90 days in patients with (aOR 6.28, 95% CI 5.40-7.31) and without (aOR 8.01, 95% CI 6.21-10.38) preoperative opioid use (Figure 2a), following cervical (aOR 6.06, 95% CI 4.74-7.76) and lumbar (aOR 7.60, 95% CI 6.27-9.24) spine surgeries (Figure 2b), as well as in patients receiving care from neurosurgery (aOR 6.24, 95% CI 5.23-7.46) and orthopedic (aOR 7.60, 95% CI 6.25-9.27) services (Figure 2c).

Predicting Opioid Refill at 61-90 Days Based on Refill at 31-60 Days After Discharge

We explored the potential of using opioid refill at 31-60 days as a screening marker to predict subsequent refill at 61-90 days. This approach yielded a negative predictive value (NPV) of

94.3% (Figure 3a). Specifically, for patients with and without pre-operative opioid use, the NPVs were 92.0% and 96.7%, respectively. For patients undergoing different spine procedures, the NPVs exceeded 91% across all procedures (ranging from 91.7% in lateral lumbar interbody fusion to 98.9% in posterior spine fusion with tumor resection), except for posterior spine fusion of ≥13 segments, which had an NPV of 87.7%. Among the seven neurosurgeons and six orthopedic surgeons who performed more than 100 procedures during the study period, the NPVs ranged from 90.6% to 96.0% (Figure 3a). The positive predictive values (PPVs) for the prediction were 41.5% for the entire cohort, and 45.0% and 32.2% for patients with and without pre-operative opioid use, respectively. For patients undergoing different spine procedures, the PPVs ranged from 23.5% to 50.0%. Among the 13 surgeons, the PPVs ranged from 26.4% to 59.4% (Figure 3b).

Opioid refill at 1-30 days after discharge can also be used to predict refill at 61-90 days (Supplementary Figure 1) or refill at 31-60 days (Supplementary Figure 2); however, it provides much lower PPVs (for 61-90 days) and NPVs (for 31-60 days).

DISCUSSION

To prevent persistent postsurgical opioid use beyond three months after surgery, it is crucial to implement interventions for high-risk patients before persistent use becomes established. However, little is known about opioid use during the transitional period of 2-3 months postoperatively. Moreover, although TPS has been proposed to prevent persistent postsurgical opioid use, there is no standardized method to identify high-risk patients. In this study, we identified independent factors associated with opioid refills prescribed at 31-60 days and 61-90 days after discharge from spine surgery, a procedure with a high incidence of persistent postsurgical opioid use[5,6]. Among these factors, opioid refill at 31-60 days was the strongest predictor of refill at 61-90 days, and the refill rates refills at 31-60 days and 61-90 days were linearly correlated. Using opioid refill at 31-60 days to predict refill at 61-90 days yielded an NPV of 94.3% and a PPV of 41.5%. Notably, the NPVs were consistently high regardless of preoperative opioid use, procedure, or surgeon.

We used opioid refill prescriptions as a proxy for opioid use in this study as prescriptions serve as a gateway for patients to access opioids[38]. We found that the strongest independent predictors of opioid refills at 31-60 days and 61-90 days were prior opioid refills. After controlling for other factors, a refill at 31-60 days after discharge was associated with a more than six-fold increase in the odds of refill at 61-90 days. This strong association persisted regardless of preoperative opioid use, whether the procedure was cervical or lumbar spine surgery, or whether care was provided by orthopedic or neurosurgical services. Conversely, refill at 1-30 days was associated with a more than three-fold increase in the odds of refill at 61-90 days and a four-fold increase in the odds of refill at 31-60 days after discharge. These findings highlight the importance of

carefully managing each postsurgical opioid refill prescription following spine surgery to prevent subsequent refills.

As prevention is widely regarded as the most effective strategy for managing chronic diseases[39], it is likely also the best approach for addressing persistent postsurgical opioid use. Therefore, the transitional phase of two to three months after surgery may represent a crucial window for implementing interventions to prevent long-term opioid use. Given the strong association and linear correlation between refills at 31-60 days and 61-90 days after discharge, an opioid refill at 31-60 days may serve as a useful screening marker to identify patients at high risk for subsequent refills at 61-90 days. This marker demonstrated an NPV of 94.3% and a PPV of 41.5%. In other words, if a patient does not receive opioid refill at 31-60 days, there is a 94.3% likelihood they will not require a refill at 61-90 days. Conversely, if a patient does receive a refill at 31-60 days, there is a 41.5% chance that they will require a refill at 61-90 days.

Therefore, it may be advisable to refer patients who receive a refill at 31-60 days after discharge to a TPS for multimodal management to prevent further opioid use following spine surgery. Since the opioid refill rate in the third month after spine surgery closely mirrors that at 12 months[5,6], TPS interventions aimed at reducing opioid refill in the third month may help reduce opioid use by 12 months. Notably, during our 7-year study period, 2,819 spine surgery patients received refills at 31-60 days after discharge (Table 1), averaging fewer than eight patients per week, well within the manageable capacity of a TPS. Although refills at 1-30 days may also serve as a screening marker for refills at 31-60 and 61-90 days, their NPVs and PPVs are considerably lower.

Since many post-operative factors are associated with opioid refills at 31-60 and 61-90 days after discharge, efforts to prevent prolonged opioid use should begin shortly after spine surgery. For example, postsurgical pain should be adequately managed. For every 1-point increase in the first pain score (on a scale of 0-10) recorded on the hospital floor, the odds of opioid refills at 31-60 and 61-90 days increased by 3% and 5%, respectively. Additionally, each 1-point increase in the last pain score recorded before discharge was associated with a 7% increase in the odds of refill at 31-60 days. Notably, postsurgical administration of acetaminophen was associated with a reduced risk of opioid refill at 61-90 days, suggesting that its use provides long-term benefit and should be encouraged after spine surgery to reduce postsurgical pain and lower the likelihood of prolonged opioid refills. However, after adjusting for other factors, intraoperative OME, the first postsurgical inpatient daily OME, and the last inpatient daily OME before discharge were not associated with increased or decreased risks of opioid refills.

Although substantial efforts have focused on reducing the total dose of discharge opioid prescriptions based on procedure-centered guidelines[40-42], our study showed that the total dose of discharge opioid prescriptions was not associated with an increased or decreased risk of opioid refills at 61-90 days after discharge. While it was associated with an increased risk of refills at 31-60 days, the effect was clinically marginal, with each 1 OME increase corresponding to only a 0.008% increase in odds, or a 0.8% increase in odds for every 100 OME increase. In contrast, opioid daily dose under-prescription, defined as the maximum daily dose of discharge opioid prescription being at least 7.5 OME lower than the patient's last inpatient daily opioid consumption before discharge, was associated with a 33% increase in the odds of opioid refills at

61-90 days. Since poorly controlled acute pain is one of the strongest predictors of chronic postsurgical pain[16], patients whose maximum daily dose of discharge opioid is lower than their daily opioid requirements may experience undertreated acute pain, placing them at higher risk of long-term pain and prolonged opioid use after spine surgery.

Preoperatively, opioid use within six months before surgery was associated with a 68% and 86% increase in the odds of opioid refills at 61-90 days and 31-60 days after discharge, respectively. Preoperative use of marijuana and benzodiazepine, as well as a history of depression, were also associated with increased risk of refills during both time periods. However, given the substantial contribution of many postsurgical factors to opioid refills, identifying high-risk patients based solely on preoperative factors can be challenging.

As an observational study, our research had the inherent limitations of unmeasured confounding variables. For example, while we investigated opioid refill prescriptions, we could not capture the actual amount of opioids consumed by the patients. However, since opioid prescription serves as a gateway for the opioids to be potentially accessed by patients and released into the community, proper prescribing practices are crucial for effective postsurgical opioid management. Additionally, although our analyses accounted for the preoperative use of opioids, marijuana, and benzodiazepines, our dataset did not include information on the preoperative use of other substances with abuse potential.

Our results suggest that each postsurgical opioid refill prescription after spine surgery should be carefully managed to prevent subsequent opioid refills. Given the strong association and linear correlation between refill rates at 31-60 and 61-90 days, an opioid refill at 31-60 days may serve as a simple yet effective screening marker to identify high-risk patients who could benefit from TPS management to reduce further opioid use after spine surgery.

REFERENCES

1. Neuman MD, Bateman BT, Wunsch H: Inappropriate opioid prescription after surgery. Lancet 2019; 393: 1547-1557
2. Harbaugh CM, Nalliah RP, Hu HM, Englesbe MJ, Waljee JF, Brummett CM: Persistent Opioid Use After Wisdom Tooth Extraction. JAMA 2018; 320: 504-506
3. Barth RJ, Jr., Waljee JF: Classification of Opioid Dependence, Abuse, or Overdose in Opioid-Naive Patients as a "Never Event". JAMA Surg 2020; 155: 543-544
4. Brown CR, Chen Z, Khurshan F, Groeneveld PW, Desai ND: Development of Persistent Opioid Use After Cardiac Surgery. JAMA Cardiol 2020; 5: 889-896
5. Pugely AJ, Bedard NA, Kalakoti P, Hendrickson NR, Shillingford JN, Laratta JL, Saifi C, Lehman RA, Riew KD: Opioid use following cervical spine surgery: trends and factors associated with long-term use. Spine J 2018; 18: 1974-1981
6. Kalakoti P, Hendrickson NR, Bedard NA, Pugely AJ: Opioid Utilization Following Lumbar Arthrodesis: Trends and Factors Associated With Long-term Use. Spine (Phila Pa 1976) 2018; 43: 1208-1216
7. Bedard NA, Pugely AJ, Westermann RW, Duchman KR, Glass NA, Callaghan JJ: Opioid Use After Total Knee Arthroplasty: Trends and Risk Factors for Prolonged Use. J Arthroplasty 2017; 32: 2390-2394
8. Bedard NA, Pugely AJ, Dowdle SB, Duchman KR, Glass NA, Callaghan JJ: Opioid Use Following Total Hip Arthroplasty: Trends and Risk Factors for Prolonged Use. J Arthroplasty 2017; 32: 3675-3679
9. Westermann RW, Anthony CA, Bedard N, Glass N, Bollier M, Hettrich CM, Wolf BR: Opioid Consumption After Rotator Cuff Repair. Arthroscopy 2017; 33: 1467-1472
10. Anthony CA, Westermann RW, Bedard N, Glass N, Bollier M, Hettrich CM, Wolf BR: Opioid Demand Before and After Anterior Cruciate Ligament Reconstruction. Am J Sports Med 2017; 45: 3098-3103
11. Bedard NA, DeMik DE, Dowdle SB, Callaghan JJ: Trends and risk factors for prolonged opioid use after unicompartmental knee arthroplasty. Bone Joint J 2018; 100-B: 62-67
12. Gerlach EB, Plantz MA, Swiatek PR, Wu SA, Arpey N, Fei-Zhang D, Divi SN, Hsu WK, Patel AA: The Drivers of Persistent Opioid Use and Its Impact on Healthcare Utilization After Elective Spine Surgery. Global Spine J 2024; 14: 370-379
13. Porter ED, Sacks OA, Ramkumar N, Barth RJ, Jr.: Surgery Prescription Opioid Misuse and Diversion in US Adults and Associated Risk Factors. J Surg Res 2022; 275: 208-217
14. Agniel D, Brat GA, Marwaha JS, Fox K, Knecht D, Paz HL, Bicket MC, Yorkgitis B, Palmer N, Kohane I: Association of Postsurgical Opioid Refills for Patients With Risk of Opioid Misuse and Chronic Opioid Use Among Family Members. JAMA Netw Open 2022; 5: e2221316
15. Brat GA, Agniel D, Beam A, Yorkgitis B, Bicket M, Homer M, Fox KP, Knecht DB, McMahill-Walraven CN, Palmer N, Kohane I: Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ 2018; 360: j5790
16. Hollmann MW, Rathmell JP, Lirk P: Optimal postoperative pain management: redefining the role for opioids. Lancet 2019; 393: 1483-1485

17. Sun EC, Darnall BD, Baker LC, Mackey S: Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Intern Med 2016; 176: 1286-93
18. Schoenfeld AJ, Jiang W, Chaudhary MA, Scully RE, Koehlmoos T, Haider AH: Sustained Prescription Opioid Use Among Previously Opioid-Naive Patients Insured Through TRICARE (2006-2014). JAMA Surg 2017; 152: 1175-1176
19. Parikh MA, Fabiyi C, Mistry KB: Factors Associated With Postprocedure Opioid Prescribing and Persistent Opioid Use Among Opioid-naive Patients: A Nationally Representative Sample. Ann Surg 2022; 276: e706-e713
20. Soneji N, Clarke HA, Ko DT, Wijeysundera DN: Risks of Developing Persistent Opioid Use After Major Surgery. JAMA Surg 2016; 151: 1083-1084
21. Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, Bohnert ASB, Kheterpal S, Nallamothu BK: New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg 2017; 152: e170504
22. Cram P, Landon BE, Matelski J, Ling V, Perruccio AV, Paterson JM, Rampersaud YR: Utilization and Outcomes for Spine Surgery in the United States and Canada. Spine (Phila Pa 1976) 2019; 44: 1371-1380
23. Larach DB, Sahara MJ, As-Sanie S, Moser SE, Urquhart AG, Lin J, Hassett AL, Wakeford JA, Clauw DJ, Waljee JF, Brummett CM: Patient Factors Associated With Opioid Consumption in the Month Following Major Surgery. Ann Surg 2021; 273: 507-515
24. Sun EC, Rishel CA, Waljee JF, Brummett CM, Jena AB: Association Between State Limits on Opioid Prescribing and the Incidence of Persistent Postoperative Opioid Use Among Surgical Patients. Ann Surg 2023; 277: e759-e765
25. Fernandez AC, Bohnert A, Gunaseelan V, Motamed M, Waljee JF, Brummett CM: Identifying Persistent Opioid Use After Surgery: The Reliability of Pharmacy Dispensation Databases. Ann Surg 2023; 278: e20-e26
26. Goyal A, Payne S, Sangaralingham LR, Jeffery MM, Naessens JM, Gazelka HM, Habermann EB, Krauss W, Spinner RJ, Bydon M: Incidence and risk factors for prolonged postoperative opioid use following lumbar spine surgery: a cohort study. J Neurosurg Spine 2021: 1-9
27. O'Hara NN, Pollak AN, Welsh CJ, O'Hara LM, Kwok AK, Herman A, Slobogean GP: Factors Associated With Persistent Opioid Use Among Injured Workers' Compensation Claimants. JAMA Netw Open 2018; 1: e184050
28. Wang MC, Lozen AM, Laud PW, Nattinger AB, Krebs EE: Factors associated with chronic opioid use after cervical spine surgery for degenerative conditions. J Neurosurg Spine 2019: 1-8
29. Rosenthal BD, Suleiman LI, Kannan A, Edelstein AI, Hsu WK, Patel AA: Risk Factors for Prolonged Postoperative Opioid Use After Spine Surgery: A Review of Dispensation Trends From a State-run Prescription Monitoring Program. J Am Acad Orthop Surg 2019; 27: 32-38
30. Ziino C, Karhade AV, Schoenfeld AJ, Harris MB, Schwab JH: Characteristics of postoperative opioid prescription use following lumbar discectomy. J Neurosurg Spine 2021; 35: 710-714
31. Dowell D, Haegerich TM, Chou R: CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep 2016; 65: 1-49

32. McPherson MLM, American Society of Health-System Pharmacists: Demystifying opioid conversion calculations : a guide for effective dosing, Second edition. edition. Bethesda, MD, American Society of Health-System Pharmacists, 2019

33. Campbell LJ, Mummaneni PV, Letchuman V, Langnas E, Agarwal N, Guan LS, Croci R, Vargas E, Reisner L, Bickler P, Chou D, Chang E, Guan Z: Mismatched opioid prescription in patients discharged after neurological surgeries: a retrospective cohort study. Pain 2023; 164: 2615-2621

34. Kuo J, Langnas E, Zhang L, Seth R, Guan Z: Opioid Overprescription and Underprescription to Patients After Otolaryngology-Head and Neck Surgery. JAMA Otolaryngol Head Neck Surg 2023; 149: 756-758

35. Guan LS, Langnas E, Bongiovanni T, Campbell LJ, Wick EC, Guan Z: Discharge Opioid Over- and Underprescription to Patients after General Surgery: A Retrospective Cohort Study. J Am Coll Surg 2023; 237: 332-342

36. Chen VJ, Guan LS, Bokoch MP, Langnas E, Kothari R, Croci R, Campbell LJ, Quan D, Freise C, Guan Z: Mismatched Postsurgical Opioid Prescription to Liver Transplant Patients: A Retrospective Cohort Study From a Single High-volume Transplant Center. Transplantation 2024; 108: 483-490

37. Michigan OPEN: Opioid Presribing Recommendations. https://michigan-open.org/prescribing-recommendations/

38. Waljee JF, Li L, Brummett CM, Englesbe MJ: Iatrogenic Opioid Dependence in the United States: Are Surgeons the Gatekeepers? Ann Surg 2017; 265: 728-730

39. Rattay KT, Henry LMG, Killingsworth RE: Preventing Chronic Disease:: The Vision of Public Health. Dela J Public Health 2017; 3: 52-56

40. Vu JV, Howard RA, Gunaseelan V, Brummett CM, Waljee JF, Englesbe MJ: Statewide Implementation of Postoperative Opioid Prescribing Guidelines. N Engl J Med 2019; 381: 680-682

41. Howard R, Waljee J, Brummett C, Englesbe M, Lee J: Reduction in Opioid Prescribing Through Evidence-Based Prescribing Guidelines. JAMA Surg 2018; 153: 285-287

42. Krauss WE, Habermann EB, Goyal A, Ubl DS, Alvi MA, Whipple DC, Glasgow AE, Gazelka HM, Bydon M: Impact of Opioid Prescribing Guidelines on Postoperative Opioid Prescriptions Following Elective Spine Surgery: Results From an Institutional Quality Improvement Initiative. Neurosurgery 2021; 89: 460-470

FIGURE LEGENDS

Figure 1. Rates of opioid refills at 31-60 days and 61-90 days after discharge from spine surgery.

a. The rate of opioid refill at 31-60 days after discharge significantly decreased from 2017 to 2023.

b. There is a linear relationship between the rates of opioid refills at 31-60 days and 61-90 days after discharge.

Data were analyzed using linear regression.

Figure 2. Strong association between opioid refills at 31-60 days and 61-90 days after discharge from spine surgery.

With other variables controlled, opioid refills at 31-60 days after discharge were strongly and independently associated with opioid refills at 61-90 days among patients with or without pre-operative opioids (**a**), following cervical or lumbar procedures (**b**), and across neurosurgery or orthopedics (**c**).

The other controlled variables are listed in the methods section. Data were analyzed using multiple logistic regression, with $p<0.0001$ for each analysis.

Figure 3. Using opioid refill at 31-60 days after discharge to predict a refill at 61-90 days.

Negative (**a**) and positive (**b**) predictive values are presented for the whole cohort, with or without preoperative opioids, across different spine procedures, and by different surgeons. Data were analyzed using two-sided Fisher's exact test, with $p<0.0001$ for each analysis.

Table 1. Demographic data of 11,087 spine surgical patients

Age (years), median (IQR)	64 (54-72)
Self-identified sex, No. (%)	
Male	5,338 (48.1)
Female	5,744 (51.8)
Self-identified race and ethnicity, No. (%)	
Asian	883 (8.0)
Black	632 (5.7)
Native American or Alaska Natives	163 (1.5)
Native Hawaiian or Other Pacific Islander	59 (0.5)
White	8,075 (72.8)
Hispanic or Latino	1,151 (10.4)
Opioid refill prescription after discharge, No. (%)	
1-30 days	4,151 (37.4)
31-60 days	2,819 (25.4)
61-90 days	1,640 (14.8)
Pre-op medications, No. (%)	
Opioids (up to 6 months before surgery)	6,243 (56.3)
Marijuana	2,115 (19.1)
Benzodiazepine	2,071 (18.7)
Opioid dosage (OME), median (IQR)	
Intra-op	106.6 (67.2-204.0)
Postoperative first inpatient daily on hospital floor	110.0 (55.8-199.8)
Last inpatient daily before discharge	75.0 (30.0-132.5)
Discharge prescription total dose	450.0 (0.0-900.0)
Discharge opioid prescription	
Daily dose over-prescription	5,149 (46.4)
Daily dose matched prescription	1,500 (13.5)
Daily dose under-prescription	4,438 (40.0)
Pain level, median (IQR)	
First postsurgical floor pain level	6 (3-8)
Last pain level before discharge	5 (3-6)
Post-op non-opioid analgesic, No. (%)	
Acetaminophen	10,386 (93.7)
Nonsteroidal anti-inflammatory drug (NSAID)	399 (3.6)
Gabapentinoid	9974 (90.0)
Psychiatric comorbidity, No. (%)	
Depression	194 (1.7)
Anxiety	88 (0.8)
Characteristics of surgery, No. (%)	
Neurosurgery	7,127 (64.3)
Orthopedic surgery	3,960 (35.7)
Cervical procedures	3,498 (31.6)
Lumbar procedures	4,770 (43.02)
Laminectomy	2,683 (24.2)
Tumor resection	415 (3.7)
Spine fusion	7,989 (72.1)
Elective procedures	10,083 (90.9)
Return to operating room before discharge	1,938 (17.5)
Discharge to home or self-care	3,712 (33.5)
Individual procedure, No. (%)	
Anterior cervical discectomy and fusion (ACDF)	1,317 (11.9)
Anterior lumbar spine fusion 2-4 segments	1,005 (9.1)
Cervical laminoplasty	363 (3.3)
Endoscopic posterior spine fusion 1-2 segment	361 (3.3)
Laminectomy for spinal cord tumor resection	205 (1.8)
Lateral Lumbar Interbody Fusion (LLIF)	281 (2.5)
Lumbar decompression	722 (6.5)
Posterior cervical spine fusion 4-7 segments	804 (7.3)
Posterior lumbar spine fusion 1-3 segments	651 (5.9)
Posterior lumbar spine fusion 4-6 segments	369 (3.3)
Posterior spine fusion 7-12 segments	644 (5.8)
Posterior spine fusion ≥13 segments	234 (2.1)
Posterior spine fusion with resection of spine tumor	120 (1.1)
Procedure length (min) , median (IQR)	192 (131-282)
Post-op hospital length of stay (LOS) (days) , median (IQR)	4 (3-7)
BMI, median (IQR)	27.6 (24.1-32.1)

Table 2. Independent risk factors associated with opioid refill prescriptions 61-90 and 31-60 days after discharge from spine surgeries. aOR: adjusted odds ratio; CI: confidence interval.

Variables	Refill 61-90 days after discharge		Refill 31-60 days after discharge	
	aOR	95% CI	aOR	95% CI
Opioid refill 31-60d	6.71	5.90-7.65		
Opioid refill 1-30d	3.16	2.76-3.62	4.04	3.66-4.46
Pre-op opioids (up to 6 months before surgery)	1.68	1.45-1.95	1.86	1.67-2.08
Pre-op marijuana	1.25	1.08-1.45	1.26	1.12-1.42
Pre-op benzodiazepine	1.17	1.01-1.35	1.16	1.03-1.30
1st postsurgical floor pain level (VAS score)	1.05	1.02-1.07	1.03	1.02-1.05
Last pain level before discharge (VAS score)	1.02	0.99-1.05	1.07	1.05-1.09
Intra-op OME	0.99998	0.99988-1.00001	0.99999	0.99997-1.00001
Post-op 1st inpatient daily OME on hospital floor	1.00004	0.99987-1.00020	1.00011	0.99996-1.00030
Post-op last inpatient daily OME before discharge	1.00030	0.99977-1.00081	0.99963	0.99918-1.00006
Discharge prescription total OME	1.00004	1.00000-1.00009	1.00008	1.00004-1.00012
Opioid daily dose under-prescription at discharge	1.33	1.08-1.64	1.12	0.96-1.32
Opioid daily dose over-prescription at discharge	1.12	0.91-1.38	0.89	0.77-1.04
Post-op acetaminophen	0.55	0.43-0.72	0.85	0.69-1.05
Post-op NSAID	0.77	0.54-1.08	0.76	0.58-0.98
Post-op gabapentinoids	0.98	0.78-1.22	0.94	0.79-1.11
Discharge to home or self-care	0.82	0.70-0.96	0.84	0.75-0.95
Neurosurgery (vs orthopedics)	0.64	0.55-0.73	0.67	0.60-0.74
Elective procedure	1.05	0.81-1.36	1.03	0.85-1.24
Laminectomy	0.74	0.50-1.08	0.77	0.56-1.06
Tumor resection	0.53	0.21-1.26	1.59	0.86-2.89
Spine fusion	0.76	0.51-1.12	1.10	0.80-1.52
Cervical procedures	1.08	0.81-1.43	0.96	0.77-1.20
Lumbar procedures	0.97	0.76-1.24	1.06	0.88-1.28
Procedure length (min)	1.0004	0.9999-1.0010	1.0003	0.9999-1.0007
Return to operating room before discharge	1.02	0.85-1.22	1.07	0.93-1.22
Post-op hospital length of stay (days)	1.00	0.99-1.02	1.00	0.99-1.01
Anterior cervical discectomy and fusion (ACDF)	1.05	0.79-1.41	1.00	0.80-1.25
Anterior spine fusion 2-4 segments	1.11	0.87-1.42	1.30	1.07-1.57
Cervical laminoplasty	0.77	0.47-1.23	1.23	0.86-1.75
Endoscopic posterior spine fusion 1-2 segments	0.58	0.36-0.91	0.98	0.72-1.34
Lateral lumbar interbody fusion (LLIF)	1.09	0.75-1.57	1.11	0.82-1.48
Laminectomy for spinal cord tumor resection	1.09	0.41-3.06	0.63	0.33-1.22
Lumbar decompression	0.72	0.48-1.07	0.87	0.64-1.16
Posterior cervical spine fusion 4-7 segments	0.91	0.66-1.26	1.05	0.82-1.34
Posterior lumbar spine fusion 1-3 segments	1.11	0.84-1.48	1.09	0.88-1.37
Posterior lumbar spine fusion 4-6 segments	1.21	0.85-1.70	1.19	0.91-1.56
Posterior spine fusion 7-12 segments	0.84	0.61-1.15	1.37	1.08-1.74
Posterior spine fusion ≥ 13 segments	1.37	0.89-2.08	1.32	0.93-1.85
Posterior spine fusion with resection of spine tumor	1.65	0.60-4.72	0.82	0.41-1.64
Age (years)	1.000	0.994-1.005	0.9964	0.9924-1.0004
Female	0.99	0.87-1.13	1.06	0.96-1.17
Depression	2.03	1.38-2.99	1.404	1.002-1.962
Anxiety	1.54	0.83-2.76	0.79	0.47-1.32
BMI	1.008	0.998-1.018	1.002	0.995-1.010
Asian	1.40	0.99-1.97	0.94	0.72-1.22
Black	1.47	1.05-2.04	1.20	0.93-1.56
Native American or Alaska Native	1.42	0.85-2.32	1.07	0.71-1.59
Native Hawaiian or Other Pacific Islander	1.58	0.68-3.41	0.98	0.49-1.88
White	0.97	0.76-1.24	0.91	0.76-1.10
Hispanic or Latino	0.93	0.72-1.19	1.09	0.90-1.32


a
Opioid Refill (%)
40
30
20
10
0
2017
2018
2019
2020
2021
2022
2023
31-60d
61-90d
p=0.003
p=0.09
b
61-90d Refill (%)
20
18
16
14
12
10
22
24
26
28
30
31-60d Refill (%)
p<0.0001

Figure 1


a
Opioid Refill 61-90d
Pre-op opioids
No pre-op opioids
0
3
6
9
12
Opioid Refill 31-60d (aOR)
b
Opioid Refill 61-90d
Cervical procedures
Lumbar procedures
0
2
4
6
8
10
Opioid Refill 31-60d (aOR)
c
Opioid Refill 61-90d
Orthopedics
Neurosurgery
0
2
4
6
8
10
Opioid Refill 31-60d (aOR)

Figure 2


a
Negative predictive value (%)
100
80
60
40
20
0
Whole cohort
No pre-op opioids
Pre-op opioids
Anterior cervical discectomy and fusion (ACDF)
Anterior lumbar spine fusion 2-4 segments
Cervical laminoplasty
Endoscopic posterior spine fusion 1-2 segments
Laminectomy for spinal cord tumor resection
Lateral Lumbar Interbody Fusion (LLIF)
Lumbar decompression
Posterior cervical spine fusion 4-7 segments
Posterior lumbar spine fusion 1-3 segments
Posterior lumbar spine fusion 4-6 segments
Posterior spine fusion 7-12 segments
Posterior spine fusion ≥13 segments
Posterior spine fusion with tumor resection
Neurosurgeon 1
Neurosurgeon 2
Neurosurgeon 3
Neurosurgeon 4
Neurosurgeon 5
Neurosurgeon 6
Neurosurgeon 7
Ortho Surgeon 1
Ortho Surgeon 2
Ortho Surgeon 3
Ortho Surgeon 4
Ortho Surgeon 5
Ortho Surgeon 6
b
Positive predictive value (%)
60
40
20
0
Whole cohort
No pre-op opioids
Pre-op opioids
Anterior cervical discectomy and fusion (ACDF)
Anterior lumbar spine fusion 2-4 segments
Cervical laminoplasty
Endoscopic posterior spine fusion 1-2 segments
Laminectomy for spinal cord tumor resection
Lateral Lumbar Interbody Fusion (LLIF)
Lumbar decompression
Posterior cervical spine fusion 4-7 segments
Posterior lumbar spine fusion 1-3 segments
Posterior lumbar spine fusion 4-6 segments
Posterior spine fusion 7-12 segments
Posterior spine fusion ≥13 segments
Posterior spine fusion with tumor resection
Neurosurgeon 1
Neurosurgeon 2
Neurosurgeon 3
Neurosurgeon 4
Neurosurgeon 5
Neurosurgeon 6
Neurosurgeon 7
Ortho Surgeon 1
Ortho Surgeon 2
Ortho Surgeon 3
Ortho Surgeon 4
Ortho Surgeon 5
Ortho Surgeon 6

Figure 3